ATLANTA – Gilead Sciences Inc.'s Kite Pharma unit lifted the lid for investors on eagerly awaited long-term follow-up data from the pivotal Zuma-1 study with approved chimeric antigen receptor T (CAR T) therapy Yescarta (axicabtagene ciloleucel) in patients with relapsed or refractory non-Hodgkin's lymphoma (NHL).